Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | YWHAZ | P63104 | 1/20 | 0.31 |
| ▸ | TACR1 | P25103 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.31 |
| ▸ | GYPA | P02724 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411309 | 0.88 | L3MBTL1 (0.36) | L3MBTL1 | |
| SCHEMBL13458030 | 0.86 | YWHAZ (0.32) | YWHAZ | |
| SCHEMBL12411310 | 0.86 | NT5E (0.37) | L3MBTL1 | |
| SCHEMBL10148633 | 0.81 | L3MBTL1 (0.38) | L3MBTL1SLC6A2MEN1KMT2AYWHAZ | |
| SCHEMBL7154934 | 0.79 | MEN1 (0.41) | L3MBTL1SLC6A2MEN1KMT2AYWHAZ | |
| SCHEMBL15481393 | 0.79 | L3MBTL1 (0.39) | L3MBTL1SLC6A2MEN1KMT2ATACR1 | |
| SCHEMBL7948116 | 0.77 | NT5E (0.41) | L3MBTL1SLC6A2 | |
| SCHEMBL6567769 | 0.74 | L3MBTL1 (0.39) | L3MBTL1SLC6A2MEN1KMT2AYWHAZ | |
| SCHEMBL10831460 | 0.74 | L3MBTL1 (0.39) | L3MBTL1SLC6A2MEN1KMT2AYWHAZ | |
| SCHEMBL7151120 | 0.74 | L3MBTL1 (0.45) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166078-A1 | OLIGOSACCHARIDE COMPOUNDS FOR USE IN MOBILISING STEM CELLS | ENDOTIS PHARMA | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166078-A1 | OLIGOSACCHARIDE COMPOUNDS FOR USE IN MOBILISING STEM CELLS | CXCL12, CCL11, FUT6 | L3MBTL1 3508/4885SLC6A2 2686/4885MEN1 2164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.